Chronic radicular low back pain in the elderly
Conditions
Interventions
DEX Group:During the first treatment, 30 minutes before pain treatment, intranasal dexmedetomidine was administered (one spray per nostril, 25 µg per spray) and intravenous placebo (2 ml of 0.9% salin
during the second treatment, 30 minutes before pain treatment, intranasal placebo (one spray per nostril of 0.9% saline) and intravenous midazolam (0.05 mg/kg) were administered. In this study's cross
MID group:During the first treatment, 30 minutes before pain treatment, a nasal spray placebo (1 spray in each nostril of 0.9% saline) was administered and intravenous midazolam (0.05 mg/kg) was given
during the second treatment, 30 minutes before pain treatment, a nasal spray of dexmedetomidine (1 spray in each nostril, 25 µg per spray) was administered and an intravenous placebo (2 ml of 0.9% sal
Sponsors
Beijing Jishuitan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 60 years; 2.Within 30 days, it is planned to perform the same invasive pain treatment procedure two times or more, including lumbar nerve root block and lumbar nerve root radiofrequency ablation. 3.At the time of the consultation, the pain intensity was>=4 on the Visual Analog Scale (VAS). 4.The subjects signed informed consent forms.
Exclusion criteria
Exclusion criteria: 1.Patients with known allergy or intolerance to dexmedetomidine or midazolam. 2.Psychomotor agitation; 3.There is a documented risk of aspiration: bowel obstruction, vomiting, nausea, and clinically relevant gastroesophageal reflux. 4.Risk factors for respiratory distress include: recent (20 breaths/minute), and known sleep apnea without non-invasive ventilatory support. 5.Contraindications for nasal medications: Nasal trauma or obstruction: excessive mucus, bleeding, anatomical abnormalities, tumors, or foreign body obstruction. 6.Cardiac risk factors: Recent (<7 days) congestive heart failure, known life-threatening arrhythmias or conduction disorders, heart rate <60 beats/minute or second- or third-degree atrioventricular block without a pacemaker, systolic blood pressure <=100 mmHg, digitalis therapy. 7.The researchers determined that the participants were not suitable for the trial. 8.The patient participated in other studies concurrently, which seriously impacted this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ramsay Sedation Score (RSS score); | — |
Secondary
| Measure | Time frame |
|---|---|
| Iowa Anesthesia Satisfaction Score;Incidence of adverse reactions;VAS score;Depression;Oswestry Disability Index (ODI);Anxiety;Cognitive function;Sleep disorders;RSS rating;Quality of life; | — |
Countries
China
Contacts
Public ContactYan Zhou
Beijing Jishuitan Hospital, Capital Medical University
Outcome results
None listed